Publications

• Long-term 3D cell culture models for hepatitis B virus studies.
  Virology Volume: 600 Page(s): 110265
  12/01/2024 Authors: Jones CE; Dangas G; Norris AC; Koenig M; Li D-Y; Shue TM; Athanasiadis A; Barbosa L; Zhou Y; Levenson KC
• Myrtus communis L. Essential Oil Exhibits Antiviral Activity against Coronaviruses.
  Pharmaceuticals (Basel) Volume: 17
  09/10/2024 Authors: Li D-Y; Donadu MG; Shue T; Dangas G; Athanasiadis A; Lan S; Wen X; Battah B; Zanetti S; Mazzarello V
• A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.
  PLoS Biol Volume: 22 Page(s): e3002767
  09/01/2024 Authors: Le Pen J; Paniccia G; Kinast V; Moncada-Velez M; Ashbrook AW; Bauer M; Hoffmann H-H; Pinharanda A; Ricardo-Lax I; Stenzel AF
• WNTinib is a multi-kinase inhibitor with specificity against -catenin mutant hepatocellular carcinoma.
  Nat Cancer Volume: 4 Page(s): 1157 - 1175
  08/01/2023 Authors: Rialdi A; Duffy M; Scopton AP; Fonseca F; Zhao JN; Schwarz M; Molina-Sanchez P; Mzoughi S; Arceci E; Abril-Fornaguera J
• Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus.
  Viruses Volume: 15
  04/17/2023 Authors: Liu D; Ndongwe TP; Ji J; Huber AD; Michailidis E; Rice CM; Ralston R; Tedbury PR; Sarafianos SG
• An RNA-based system to study hepatitis B virus replication and evaluate antivirals.
  Sci Adv Volume: 9 Page(s): eadg6265
  04/14/2023 Authors: Yu Y; Schneider WM; Kass MA; Michailidis E; Acevedo A; Pamplona Mosimann AL; Bordignon J; Koenig A; Livingston CM; van Gijzel H
• Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.
  Science Volume: 379 Page(s): eabo3627
  02/10/2023 Authors: Lee D; Le Pen J; Yatim A; Dong B; Aquino Y; Ogishi M; Pescarmona R; Talouarn E; Rinchai D; Zhang P
• HIV nucleoside reverse transcriptase inhibitors.
  Eur J Med Chem Volume: 240 Page(s): 114554
  10/05/2022 Authors: Amblard F; Patel D; Michailidis E; Coats SJ; Kasthuri M; Biteau N; Tber Z; Ehteshami M; Schinazi RF
• ALCOHOLIC STEATOSIS IN LIVER CHIMERIC MICE IS WORSENED BY PNPLA3 148M IN HUMAN HEPATOCYTES
  Volume: 76 Page(s): S985 - S985
  10/01/2022 Authors: Quirk C; Zou C; Kabbani M; Powell K-M; Upadhyay A; Zeck B; Foquet L; Chiriboga L; Michailidis E; Fulmer CG
• HUMAN HEPATOCYTE EXPANSION POTENTIAL IN CHIMERIC MICE
  Volume: 76 Page(s): S510 - S510
  10/01/2022 Authors: Michailidis E; Schneider WM; Freije C; Zou C; Yu Y; Quirk C; Vercauteren K; Kabbani M; Zeck B; Ashbrook AW
• Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
  Cell Rep Volume: 40 Page(s): 111321
  09/13/2022 Authors: Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C
• The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
  Proc Natl Acad Sci U S A Volume: 119 Page(s): e2200413119
  05/24/2022 Authors: Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann H-H; Eto S; Garcia-Prat M
• The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies.
  Res Sq
  01/14/2022 Authors: Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann H-H; Eto S; Garcia-Prat M
• RNR-R2 Upregulation by a Short Non-Coding Viral Transcript.
  Biomolecules Volume: 11
  12/03/2021 Authors: Broennimann K; Ricardo-Lax I; Adler J; Michailidis E; de Jong YP; Reuven N; Shaul Y
• Replication and single-cycle delivery of SARS-CoV-2 replicons.
  Science Volume: 374 Page(s): 1099 - 1106
  11/26/2021 Authors: Ricardo-Lax I; Luna JM; Thao TTN; Le Pen J; Yu Y; Hoffmann H-H; Schneider WM; Razooky BS; Fernandez-Martinez J; Schmidt F
• Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
  Antimicrob Agents Chemother Volume: 65 Page(s): e0116721
  11/17/2021 Authors: Cilento ME; Reeve AB; Michailidis E; Ilina TV; Nagy E; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
• PNPLA3-148M IMPAIRS LIPID MOBILIZATION IN PRIMARY HUMAN HEPATOCYTE CULTURES
  Volume: 74 Page(s): 1082A - 1083A
  10/01/2021 Authors: Kabbani M; Michailidis E; Steensels S; Tardelli M; Le Pen J; Haczeyni F; Luna JM; Ricardo-Lax I; Zou C; Stenzel AF
• Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening.
  Volume: 11 Page(s): 2544 - 2563
  10/01/2021 Authors: Lalazar G; Requena D; Ramos-Espiritu L; Ng D; Bhola PD; de Jong YP; Wang R; Narayan NJC; Shebl B; Levin S
• Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
  Sci Immunol Volume: 6
  08/19/2021 Authors: Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann H-H; Eto S; Garcia-Prat M
• Primary human hepatocyte gene editing: Prometheus' chains are loosening.
  Mol Ther Volume: 29 Page(s): 1666 - 1667
  05/05/2021 Authors: Michailidis E; de Jong YP
• Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
  J Exp Med Volume: 218
  04/05/2021 Authors: Bastard P; Michailidis E; Hoffmann H-H; Chbihi M; Le Voyer T; Rosain J; Philippot Q; Seeleuthner Y; Gervais A; Materna M
• Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors.
  Cell Host Microbe Volume: 29 Page(s): 267 - 280.e5
  02/10/2021 Authors: Hoffmann H-H; Snchez-Rivera FJ; Schneider WM; Luna JM; Soto-Feliciano YM; Ashbrook AW; Le Pen J; Leal AA; Ricardo-Lax I; Michailidis E
• Enhanced SARS-CoV-2 neutralization by dimeric IgA.
  Sci Transl Med Volume: 13
  01/20/2021 Authors: Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Viant C; Gaebler C; Cipolla M; Hoffmann H-H; Oliveira TY; Oren DA
• Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks.
  Cell Volume: 184 Page(s): 120 - 132.e14
  01/07/2021 Authors: Schneider WM; Luna JM; Hoffmann H-H; Snchez-Rivera FJ; Leal AA; Ashbrook AW; Le Pen J; Ricardo-Lax I; Michailidis E; Peace A
• DRUL for school: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2.
  PLoS One Volume: 16 Page(s): e0252949
  01/01/2021 Authors: Frank MO; Blachere NE; Parveen S; Hacisuleyman E; Fak J; Luna JM; Michailidis E; Wright S; Stark P; Campbell A
• Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
  J Exp Med Volume: 217
  11/02/2020 Authors: Schmidt F; Weisblum Y; Muecksch F; Hoffmann H-H; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C
• LY6E impairs coronavirus fusion and confers immune control of viral disease.
  Nat Microbiol Volume: 5 Page(s): 1330 - 1339
  11/01/2020 Authors: Pfaender S; Mar KB; Michailidis E; Kratzel A; Boys IN; V'kovski P; Fan W; Kelly JN; Hirt D; Ebert N
• Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice.
  Sci Adv Volume: 6
  11/01/2020 Authors: Brown RJP; Tegtmeyer B; Sheldon J; Khera T; Anggakusuma; Todt D; Vieyres G; Weller R; Joecks S; Zhang Y
• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
  Elife Volume: 9
  10/28/2020 Authors: Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann H-H; Michailidis E
• Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
  Science Volume: 370
  10/23/2020 Authors: Zhang Q; Bastard P; Liu Z; Le Pen J; Moncada-Velez M; Chen J; Ogishi M; Sabli IKD; Hodeib S; Korol C
• Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
  Science Volume: 370
  10/23/2020 Authors: Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann H-H; Zhang Y; Dorgham K; Philippot Q; Rosain J; Bziat V
• Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks.
  bioRxiv
  10/08/2020 Authors: Schneider WM; Luna JM; Hoffmann H-H; Snchez-Rivera FJ; Leal AA; Ashbrook AW; Le Pen J; Michailidis E; Ricardo-Lax I; Peace A
• Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors.
  bioRxiv
  09/11/2020 Authors: Hoffmann H-H; Schneider WM; Snchez-Rivera FJ; Luna JM; Ashbrook AW; Soto-Feliciano YM; Leal AA; Le Pen J; Ricardo-Lax I; Michailidis E
• Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice.
  Mol Ther Methods Clin Dev Volume: 18 Page(s): 189 - 198
  09/11/2020 Authors: Zou C; Vercauteren KOA; Michailidis E; Kabbani M; Zoluthkin I; Quirk C; Chiriboga L; Yazicioglu M; Anguela XM; Meuleman P
• Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro.
  bioRxiv
  09/09/2020 Authors: Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Viant C; Gaebler C; Cipolla M; Hoffman H-H; Oliveira TY; Oren DA
• A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.
  Cell Host Microbe Volume: 28 Page(s): 335 - 349.e6
  08/12/2020 Authors: Wang Q; Michailidis E; Yu Y; Wang Z; Hurley AM; Oren DA; Mayer CT; Gazumyan A; Liu Z; Zhou Y
• Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
  Nature Volume: 584 Page(s): 437 - 442
  08/01/2020 Authors: Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S
• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
  bioRxiv
  07/22/2020 Authors: Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JCC; Muecksch F; Rutkowska M; Hoffmann H-H; Michailidis E
• Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
  bioRxiv
  06/09/2020 Authors: Schmidt F; Weisblum Y; Muecksch F; Hoffmann H-H; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C
• Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
  bioRxiv
  05/22/2020 Authors: Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S
• LY6E impairs coronavirus fusion and confers immune control of viral disease.
  bioRxiv
  03/07/2020 Authors: Pfaender S; Mar KB; Michailidis E; Kratzel A; Hirt D; V'kovski P; Fan W; Ebert N; Stalder H; Kleine-Weber H
• Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.
  Proc Natl Acad Sci U S A Volume: 117 Page(s): 1678 - 1688
  01/21/2020 Authors: Michailidis E; Vercauteren K; Mancio-Silva L; Andrus L; Jahan C; Ricardo-Lax I; Zou C; Kabbani M; Park P; Quirk C
• Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus.
  Viruses Volume: 11
  11/08/2019 Authors: Liu D; Tedbury PR; Lan S; Huber AD; Puray-Chavez MN; Ji J; Michailidis E; Saeed M; Ndongwe TP; Bassit LC
• PNPLA3-148M OVEREXPRESSION IN PRIMARY HUMAN HEPATOCYTES EXACERBATES STEATOSIS IN TISSUE CULTURE AND CHIMERIC MOUSE MODELS OF NAFLD
  Volume: 70 Page(s): 1325A - 1326A
  10/01/2019 Authors: Kabbani M; Michailidis E; Steensels S; Zou C; Zeck B; Inna R-L; Fulmer CG; Quirk C; Ashbrook AW; Belkaya S
• Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP).
  J Virol Volume: 93
  09/15/2019 Authors: Li MMH; Aguilar EG; Michailidis E; Pabon J; Park P; Wu X; de Jong YP; Schneider WM; Molina H; Rice CM
• Inherited IL-18BP deficiency in human fulminant viral hepatitis.
  J Exp Med Volume: 216 Page(s): 1777 - 1790
  08/05/2019 Authors: Belkaya S; Michailidis E; Korol CB; Kabbani M; Cobat A; Bastard P; Lee YS; Hernandez N; Drutman S; de Jong YP
• Expansion and genetic modification of primary hepatocytes to study long-term hepatitis B virus infection
  Volume: 70 Page(s): E712 - E712
  04/01/2019 Authors: Michailidis E; Park P; Kabbani M; Silva LM; Yu Y; Schneider WM; Andrus L; Zou C; Vercauteren K; Jahan C
• A robust cell culture system supporting the complete life cycle of hepatitis B virus.
  Sci Rep Volume: 7 Page(s): 16616
  11/30/2017 Authors: Michailidis E; Pabon J; Xiang K; Park P; Ramanan V; Hoffmann H-H; Schneider WM; Bhatia SN; de Jong YP; Shlomai A
• 3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H.
  Antimicrob Agents Chemother Volume: 61
  06/01/2017 Authors: Huber AD; Michailidis E; Tang J; Puray-Chavez MN; Boftsi M; Wolf JJ; Boschert KN; Sheridan MA; Leslie MD; Kirby KA
• Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.
  J Hepatol Volume: 66 Page(s): 288 - 296
  02/01/2017 Authors: Xiang K-H; Michailidis E; Ding H; Peng Y-Q; Su M-Z; Li Y; Liu X-E; Dao Thi VL; Wu X-F; Schneider WM
• Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).
  Proc Natl Acad Sci U S A Volume: 113 Page(s): 9274 - 9279
  08/16/2016 Authors: Salie ZL; Kirby KA; Michailidis E; Marchand B; Singh K; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
• Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
  J Hepatol Volume: 65 Page(s): 334 - 343
  08/01/2016 Authors: Billerbeck E; Mommersteeg MC; Shlomai A; Xiao JW; Andrus L; Bhatta A; Vercauteren K; Michailidis E; Dorner M; Krishnan A
• Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.
  J Hepatol Volume: 64 Page(s): 257 - 259
  02/01/2016 Authors: Luna JM; Michailidis E; Rice CM
• Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.
  J Hepatol Volume: 63 Page(s): 789 - 796
  10/01/2015 Authors: Ricardo-Lax I; Ramanan V; Michailidis E; Shamia T; Reuven N; Rice CM; Shlomai A; Shaul Y
• CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
  Sci Rep Volume: 5 Page(s): 10833
  06/02/2015 Authors: Ramanan V; Shlomai A; Cox DBT; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
• TARGETING VIRAL DNA WITH CRISPR/Cas9 ROBUSTLY SUPPRESSES HEPATITIS B VIRUS
  Volume: 62 Page(s): S519 - S519
  04/01/2015 Authors: Shlomai A; Ramanan V; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Zhang F; Bhatia SN; Rice CM
• Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
  Antimicrob Agents Chemother Volume: 59 Page(s): 3482 - 3492
  01/01/2015 Authors: Liu D; Ji J; Ndongwe TP; Michailidis E; Rice CM; Ralston R; Sarafianos SG
• 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.
  J Biol Chem Volume: 289 Page(s): 24533 - 24548
  08/29/2014 Authors: Michailidis E; Huber AD; Ryan EM; Ong YT; Leslie MD; Matzek KB; Singh K; Marchand B; Hagedorn AN; Kirby KA
• SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.
  Antimicrob Agents Chemother Volume: 58 Page(s): 4915 - 4919
  08/01/2014 Authors: Huber AD; Michailidis E; Schultz ML; Ong YT; Bloch N; Puray-Chavez MN; Leslie MD; Ji J; Lucas AD; Kirby KA
• Native Hexameric Full-Length HIV-1 Capsid: Crystal Structure and Drug Targeting
  Volume: 70 Page(s): C696 - C696
  08/01/2014 Authors: Gres A; Kirby K; Hachiya A; Michailidis E; Pornillos O; Sugiura W; Lee K; KewalRamani V; Tanner J; Sarafianos S
• Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
  Antimicrob Agents Chemother Volume: 57 Page(s): 6254 - 6264
  12/01/2013 Authors: Kirby KA; Michailidis E; Fetterly TL; Steinbach MA; Singh K; Marchand B; Leslie MD; Hagedorn AN; Kodama EN; Marquez VE
• Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.
  Antimicrob Agents Chemother Volume: 57 Page(s): 4554 - 4558
  09/01/2013 Authors: Hachiya A; Reeve AB; Marchand B; Michailidis E; Ong YT; Kirby KA; Leslie MD; Oka S; Kodama EN; Rohan LC
• Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
  Retrovirology Volume: 10 Page(s): 65
  06/24/2013 Authors: Michailidis E; Ryan EM; Hachiya A; Kirby KA; Marchand B; Leslie MD; Huber AD; Ong YT; Jackson JC; Singh K
• The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.
  PLoS Pathog Volume: 9 Page(s): e1003125
  01/01/2013 Authors: Tavis JE; Cheng X; Hu Y; Totten M; Cao F; Michailidis E; Aurora R; Meyers MJ; Jacobsen EJ; Parniak MA
• Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.
  Cell Mol Biol (Noisy-le-grand) Volume: 58 Page(s): 187 - 195
  12/22/2012 Authors: Michailidis E; Singh K; Ryan EM; Hachiya A; Ong YT; Kirby KA; Marchand B; Kodama EN; Mitsuya H; Parniak MA
• Biochemical mechanism of HIV-1 resistance to rilpivirine.
  J Biol Chem Volume: 287 Page(s): 38110 - 38123
  11/02/2012 Authors: Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z
• HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
  J Biol Chem Volume: 287 Page(s): 29988 - 29999
  08/24/2012 Authors: Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM
• Antiviral therapies: focus on hepatitis B reverse transcriptase.
  Int J Biochem Cell Biol Volume: 44 Page(s): 1060 - 1071
  07/01/2012 Authors: Michailidis E; Kirby KA; Hachiya A; Yoo W; Hong SP; Kim S-O; Folk WR; Sarafianos SG
• Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase.
  Antimicrob Agents Chemother Volume: 56 Page(s): 2048 - 2061
  04/01/2012 Authors: Kirby KA; Marchand B; Ong YT; Ndongwe TP; Hachiya A; Michailidis E; Leslie MD; Sietsema DV; Fetterly TL; Dorst CA
• Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
  Nucleic Acids Res Volume: 40 Page(s): 345 - 359
  01/01/2012 Authors: Ndongwe TP; Adedeji AO; Michailidis E; Ong YT; Hachiya A; Marchand B; Ryan EM; Rai DK; Kirby KA; Whatley AS
• Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots.
  Int J Curr Chem Volume: 2 Page(s): 253 - 260
  10/01/2011 Authors: Michailidis E; Singh K; Kirby KA; Hachiya A; Yoo W; Hong SP; Kim S-O; Folk WR; Sarafianos SG
• The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.
  Cell Mol Biol (Noisy-le-grand) Volume: 57 Page(s): 40 - 46
  02/12/2011 Authors: Kirby KA; Singh K; Michailidis E; Marchand B; Kodama EN; Ashida N; Mitsuya H; Parniak MA; Sarafianos SG
• K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.
  PLoS One Volume: 6 Page(s): e16242
  01/13/2011 Authors: Hachiya A; Kodama EN; Schuckmann MM; Kirby KA; Michailidis E; Sakagami Y; Oka S; Singh K; Sarafianos SG
• Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.
  PLoS One Volume: 5 Page(s): e15049
  12/21/2010 Authors: Durk RC; Singh K; Cornelison CA; Rai DK; Matzek KB; Leslie MD; Schafer E; Marchand B; Adedeji A; Michailidis E
• Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.
  Viruses Volume: 2 Page(s): 606 - 638
  02/11/2010 Authors: Singh K; Marchand B; Kirby KA; Michailidis E; Sarafianos SG
• Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.
  J Biol Chem Volume: 284 Page(s): 35681 - 35691
  12/18/2009 Authors: Michailidis E; Marchand B; Kodama EN; Singh K; Matsuoka M; Kirby KA; Ryan EM; Sawani AM; Nagy E; Ashida N